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The  possibility  of  reprogramming  somatic  cells  into 
pluripotent  stem  cells  by  defined  sets  of  transcription 
factors,  which  has  been  delineated  in  landmark  dis­
coveries over the past few years [1], has removed a major 
roadblock to stem cell applications. The ability to gener­
ate patient­specific stem cells by this method has greatly 
extended the potential for autologous stem cell therapy 
and  cell  culture  models  of  specific  diseases.  As  with 
embryonic  stem  cells,  however,  these  strategies  still 
depend  on  complex  differentiation  protocols  to  derive 
mature cells of a defined specificity, a task that is often 
hindered by our limited understanding of cell fate deter­
ination.  For  practical  applications,  any  residual  cells 
escaping a differentiation stimulus engender a high risk 
of tumor formation in vivo, as pluripotent stem cells are 
tumorigenic. In addition, differentiation protocols might 
yield cell types that are close, but not identical, to the 
required mature cells. For example, hematopoietic differ­
en  tiation of pluripotent stem cells typically gives rise to 
red blood cells expressing embryonic globin genes, and it 
has  proved  more  difficult  to  induce  expression  of  the 
adult genes.
A recent series of papers has explored a short cut ­ the 
direct  conversion  of  fibroblasts  into  differentiated  cell 
types of other lineages, such as macrophage­like cells [2], 
neurons [3] or cardiomyocytes [4], without prior genera­
tion of pluripotent stem cells. This is typically achieved 
by the expression of transcription factors implicated in 
the developmental program of the desired lineage. These 
studies  used  mouse  fibroblasts,  but  a  paper  published 
recently in Nature by Mick Bhatia and colleagues (Szabo 
et  al.  [5])  shows  that  direct  lineage  conversion  is  also 
possible in human cells. The authors obtained hemato­
poietic  cells  with  multilineage  potential  by  the  ectopic 
expression  of  the  transcription  factor  OCT4  in  both 
neonatal  and  adult  human  fibroblasts.  Interestingly, 
lineage conversion did not involve passage through pluri­
potent intermediates and, in contrast to hematopoietic 
cells obtained by embryonic stem cell differentiation, the 
fibroblast­derived cells primarily expressed adult (β) and 
some fetal (ε) globins rather than embryonic (ξ) globins.
The study by Szabo et al. [5] was triggered by the obser­
vation that after expression of a standard cocktail of re­
pro  gramming factors (OCT4, SOX2, Nanog and LIN28) 
in  human  fibroblasts,  only  a  subset  of  cells  acquired 
stable and full pluripotency, whereas most cells remained 
in an intermediate state of reprogramming. The authors 
noticed that some of these cells showed a hematopoietic 
phenotype, including the expression of the pan­hemato­
poietic marker CD45, and that such colonies expressed 
OCT4,  but  not  the  other  reprogramming  factors,  at  a 
high level. Following up on this observation, Szabo et al. 
noted that expression of OCT4 on its own (but not the 
other  factors)  could  generate  CD45­positive  (CD45+) 
colonies. The hematopoietic nature of these fibroblast­
derived cells was then confirmed by a panel of classical in 
vitro and in vivo assays.
Cultivation  of  the  CD45+  colonies  in  a  cocktail  of 
hematopoietic cytokines led to their differentiation along 
multiple lineages. Colony assays, surface­marker analysis 
by flow cytometry, and cytological staining demonstrated 
the potential for myeloid lineage differentiation to macro­
phages  and  granulocytes  as  well  as  differentiation  to 
erythroid and megakaryocytic cells in the presence of the 
erythroid cytokine erythropoietin. Notably, the conver­
sion rate of the fibroblast­derived CD45+ cells in these 
assays was comparable in efficiency to that of umbilical 
cord blood cells, a common source of human hemato­
poietic progenitors. Interestingly, a subpopulation of the 
cytokine­treated  cells  appeared  to  maintain  blood  cell 
progenitor  potential,  as  indicated  by  expression  of  the 
progenitor marker CD34. This potential was confirmed 
by  their  ability  to  engraft  and  give  rise  to  blood  cells 
several  weeks  after  transplantation  into  NOD/SCID 
Il­2Rγc­null  mice  (NSG),  a  common  model  for  the 
Abstract
A recent study has generated blood cell progenitors 
with therapeutic potential by direct lineage 
conversion of human fibroblasts, thus circumventing 
reprogramming to pluripotent stem cells.
© 2010 BioMed Central Ltd
Creating a blood line from human skin
Michael H Sieweke*1,2,3,4
RESEARCH HIGHLIGHT
*Correspondence: sieweke@ciml.univ-mrs.fr 
1Centre d’Immunologie de Marseille-Luminy, Université Aix-Marseille, Campus de 
Luminy, Case 906, 13288 Marseille Cedex 09, France 
Full list of author information is available at the end of the article
Sieweke Genome Biology 2010, 11:143 
http://genomebiology.com/2010/11/12/143
© 2010 BioMed Central Ltdxenotransplantation of human cells. Although the effi  ci­
ency of transplantation was lower than that of umbilical 
cord  blood  cells  and  differentiation  was  significantly 
biased  towards  myeloid  cells,  this  is  still  a  remarkable 
demonstration of the hematopoietic progenitor potential 
of these fibroblast­derived cells.
Most notably, molecular analysis revealed that lineage 
conversion  from  fibroblasts  to  hematopoietic  cells  did 
not involve passage through a pluripotent state. OCT4­
transduced cells activated the expression of endogenous 
OCT4, but in contrast to induced pluripotent stem cells 
(iPS cells), activation of any of the other reprogramming 
factors was not observed. In addition, the cells did not 
acquire typical markers or a global gene expression signa­
ture of pluripotency, and they did not give rise to terato­
mas in vivo, a standard test of pluripotency. By contrast, 
the cells showed increased expression of hematopoietic 
transcription factors and cytokine receptors as early as 4 
hours  after  tansduction,  consistent  with  their  acquired 
responsiveness to hematopoietic cytokines. Significantly, 
this hematopoietic specification also did not involve the 
activation of genes usually associated with mesodermal 
transitions from the embryonic pluripotent state. Some 
other direct lineage conversions have also been found not 
to require dedifferentiation or a reversion to progenitor 
stages,  such  as  from  B  cells  to  macrophages  [6],  from 
pancreatic  exocrine  cells  to  pancreatic  β­cells  [7]  and 
from  fibroblasts  to  cardiomyocytes  [4].  Recent  reviews 
cover  other  examples  of  direct  lineage  reprogramming 
and discuss similarities and differences between iPS cells 
and direct lineage reprogramming in relation to normal 
cell  fate  decisions  [8,9].  It  will  now  be  important  to 
determine  the  molecular  mechanisms  and  genomic 
changes underling direct lineage conversions. A question 
of  particular  interest  will  be  whether  the  epigenetic 
signature and phenotypic stability of directly converted 
cells is equivalent to that of cells derived through success­
ive  stem  and  progenitor  cell  stages  during  normal 
development or differentiation in culture.
Perhaps the most surprising observation of the study 
by Szabo et al. [5] is that lineage conversion was achieved 
by  ectopic  expression  of  OCT4,  which  has  not  been 
impli  cated in hematopoiesis before and has been con­
sidered a stringent cellular marker of pluripotency and 
the  germline  in  normal  development.  Although  it  is 
conceivable that OCT4 could be mimicking the activity 
of  the  related  OCT1  and  OCT2  transcription  factors, 
which  play  a  role  in  hematopoiesis  and  can  bind  the 
same DNA octamer sequences as OCT4, the expression 
of OCT1 and OCT2 remained unchanged during lineage 
con  version and the ability of OCT1 and OCT2 to specify 
multilineage hematopoietic fate remains to be demon­
strated.  In  particular,  OCT1  and  OCT2  have  roles  in 
lymphoid differentiation, rather than that of the other 
hematopoietic  lineages,  and  the  fibroblast­derived 
hemato  poietic  cells  did  not  show  lymphoid  potential, 
although this may have been due to lack of appropriate 
culture conditions.
The lineage conversion achieved by Szabo et al. with 
OCT4  is  in  contrast  to  previous  experiments,  where 
lineage­converting transcription factors have been identi­
fied either by hypothesis­driven or experimental selec­
tion  from  a  pool  of  transcription  factors  with  known 
functions  in  the  normal  development  of  the  desired 
lineage. In this way, for example, the transcription factors 
C/EBPα  or  C/EBPβ  and  PU.1  were  found  to  induce  a 
macrophage fate in lymphoid cells and fibroblasts [3,8]; 
Ascl1,  Brn2/Pou3f2  and  Myt1l  to  induce  neuronal 
identity  in  fibroblasts  [3];  Gata4,  Mef2c  and  Tbx5  to 
induce  fibroblast  differentiation  to  cardiomyocytes  [4]; 
and Pdx1, Ngn3 and MafA to induce conversion of exo­
crine panceatic cells into β­islet cells [7]. Together these 
recent direct reprogramming results raise the question of 
whether there is a particular transcription factor signa­
ture for each cell type that defines its identity and from 
which one can select the appropriate cocktail of factors to 
achieve lineage conversion. It will also be important to 
deter  mine whether the nature of this cocktail depends 
not  only  on  the  identity  of  the  target  but  also  on  the 
source  cell  type.  The  transcription  factor  cocktail  of 
OCT4,  SOX2,  KLF4  and  cMyc  can  reprogram  cells  of 
many different tissues into iPS cells [1], and a combi  na­
tion of PU.1 and C/EBPαβ appears to induce a macro­
phage fate in several cell types [2,8], but such generally 
valid  reprogramming  combinations  may  not  always  be 
available  for  lineage  specification,  in  which  successive 
transcription­factor interactions drive the differentiation 
process, and the responsiveness to a lineage­converting 
factor may depend on the presence or absence of antago­
nistic  and  cooperative  factors  in  the  source  cells  [8]. 
Alternatively, epigenetic changes in response to external 
stimuli, such as cytokines or growth factors, may become 
possible upon induction of a plastic state that is suscep­
tible to lineage conversion. This latter mechanism could 
be compatible with the puzzling observation that a factor 
such as OCT4, which is implicated in pluripotency rather 
than lineage identity, can induce a hematopoietic fate in 
an unrelated cell type.
The study of Szabo et al. [5] has increased our armory 
of methods for deriving autologous cells with therapeutic 
potential  from  accessible  tissues  such  as  skin,  and  has 
provided proof of principle that direct lineage conversion 
is possible in human cells. Could this strategy be the way 
of the future ­ avoiding a detour via pluripotency and all 
its complexities? Although this might be possible, many 
questions  remain  to  be  addressed  to  identify  the  best 
strategy  for  each  application.  As  well  as  a  detailed, 
functional characterization of the directly converted cells 
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demon  stration  of  their  true  potential  in  a  therapeutic 
context,  cells  derived  by  direct  lineage  reprogramming 
lack one major advantage of pluripotent stem cells ­ the 
possibility  of  indefinite  amplification  in  culture.  This 
advantage  should  not  be  underestimated,  as  envisaged 
therapeutic and drug­screening applications require large 
numbers  of  cells.  By  generating  progenitor  cells  with 
limited  proliferative  potential,  Szabo  et  al.  go  beyond 
previous  studies  with  one­to­one  cell  conversions,  but 
proliferation  was  still  restricted  to  a  few  divisions  and 
cannot match the nearly unlimited self­renewal potential 
of pluripotent stem cells. This may not be an intractable 
problem,  however,  as  it  appears  that  extended  self­
renewal  potential  can  also  be  activated  in  functionally 
differentiated  cells  without  tumorigenic  transformation 
[10].  Differentiated  cells  thus  appear  to  be  capable  of 
more than could have been imagined only a few years 
ago, and the challenge of the coming years will be both to 
re­evaluate  cherished  conceptual  limits  and  definitions 
and to determine how this newly uncovered potential can 
be harnessed in useful applications.
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